Prenatal testDNA 3 and RHD

Non-invasive fetal free DNA test. Highly effective. Detects trisomy 21 (Down syndrome), 18 (Edwards syndrome), 13 (Patau syndrome), fetal RhD, and gender upon request. Available from the 10th week of pregnancy. Data and samples remain in the EU.

What is the test?

Prenatal testDNA 3 is a non-invasive prenatal test with high sensitivity of over 99%. It provides important information about the baby's health. The test requires only a small blood sample from the mother. This blood contains free fetal DNA, which is analyzed using advanced methods in the laboratory. This makes Prenatal testDNA 3 both safe and effective.

Additional RhD analysis determines the fetal RhD status, which is crucial for assessing the risk of Rh incompatibility, when the mother has an Rh-negative blood type and the father is Rh-positive.

When should you take the test?

Prenatal testDNA 3 and RhD is recommended for mothers with Rh-negative blood type. It is available after the 10th week of pregnancy. Almost any mother who wants to check her unborn child's health can take the test.

It is particularly recommended:

• For pregnancies after the age of 35, due to an increased risk of genetic disorders in the baby. A normal result can provide reassurance.
• When PAPP-A or combined screening indicates an increased risk of trisomy in first-trimester prenatal screening. A normal result may help avoid amniocentesis.

The test is also recommended if there have been cases of genetic disorders in previous pregnancies or family history, as well as when invasive tests are contraindicated.

The test can be performed for both singleton and twin pregnancies.

What does Prenatal testDNA 3 and RhD detect?

Prenatal testDNA 3 detects the most common trisomies: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and gender upon request. Additional RhD analysis determines the fetal RhD status.

What are the abnormalities detected in Prenatal testDNA 3?

• TRISOMY 21: Caused by an extra copy of chromosome 21 (Down syndrome). The most common genetic cause of intellectual disability, occurring in approximately 1 in 700 births. The risk increases with maternal age.
• TRISOMY 18: Caused by an extra copy of chromosome 18 (Edwards syndrome). It carries a high risk of miscarriage and severe intellectual disability. Infants with trisomy 18 often have congenital heart defects and other conditions that shorten life expectancy. It occurs in approximately 1 in 5,000 births, with the risk increasing with maternal age.
• TRISOMY 13: Caused by an extra copy of chromosome 13 (Patau syndrome). It carries a high risk of miscarriage. Babies with trisomy 13 may have heart defects and other conditions, making survival beyond the first year rare. It occurs in approximately 1 in 16,000 births, with the risk increasing with maternal age.

Why take the test?

Prenatal testDNA 3 provides important information about the baby's health before birth. A normal result can offer peace of mind and help avoid invasive tests such as amniocentesis.

Determining fetal RhD status helps assess the risk of Rh incompatibility in Rh-negative mothers.

• EFFECTIVE – High sensitivity confirmed in extensive clinical validation on over 70,000 pregnancies. Sensitivity for trisomy 21, 13, and 18 exceeds 99%.
• RELIABLE – The laboratory has extensive experience in non-invasive prenatal testing and has performed over 300,000 NIPT tests.
• SAFE AND SIMPLE – Requires only a small blood sample from the mother, with home collection available and online results.
• ACCESSIBLE – Available at over 300 collection points or via home sampling.

Prenatal testDNA is performed using CE-IVD certified software, equipment, and reagents in an accredited laboratory (UNI EN ISO 15189:2013, no. 0018M).

Prenatal testDNA guarantees that samples and data remain within the European Union.

How does it stand out among other NIPTs?

Confirmed high accuracy. The effectiveness of Prenatal testDNA has been validated in a large study involving over 70,000 pregnancies. Unlike other tests, this validation was conducted at a single facility, ensuring more accurate evaluation.

• Heparin use is allowed before the test. Unlike some other prenatal tests, Prenatal testDNA does not require stopping this medication before sample collection.
• Fast online results. Results are available in a secure patient portal within 4-8 business days (from the sample's arrival at the laboratory).
• Additional RhD analysis for crucial information regarding the baby's health.

Your sample and data remain within the European Union – they are not transferred outside the EU.

What does the test price include?

The price includes:

• Analysis for genetic abnormalities and gender (upon request) according to the selected package, with online results available in a secure patient portal.
• Sample collection at over 300 locations or at home (nurse visit available across Poland).
• Consultation with a clinical geneticist if abnormalities are detected (positive result). The doctor explains the result and advises on further steps.

Guidelines on “How to interpret the result” developed in collaboration with a clinical geneticist to make understanding the result even easier.

Preparation for the Test

• Fasting is not required, you can eat a meal.
• Heparin can be taken, no need to stop the medication or change its dosage.
• We recommend drinking fluids the day before and on the day of sample collection to stay hydrated.
• Check the list of contraindications in the last section. If you have any doubts, contact us. 

Step-by-Step Testing Process

1. After purchasing the test, our medical consultant will contact you to schedule an appointment at a location near you (you can choose from 300 facilities across Poland or opt for home sample collection by a visiting nurse).
2. On the scheduled date, visit the selected facility or wait for the home visit from the nurse.
3. During the visit, a test request form is signed. A sample of the documents will be sent via email for prior review.
4. A blood sample is collected from the mother’s vein, similar to a standard blood test. The sample collection is quick, and the entire visit at the facility or at home usually takes up to 20 minutes.
5. The sample, along with the request form, is sent to the Eurofins Genoma laboratory in Italy for analysis. The transportation of the sample is fast, taking only 1-2 business days, similar to deliveries to a laboratory in Poland. The transport is safe, carried out via a special DHL Medical Express shipment at room temperature (samples are not refrigerated).
6. The test result is available for download online in the secure Patient Panel. This is an official document signed electronically.
7. The waiting time for Prenatal testDNA 3 results is 4-8 days, and for RhD, up to 14 days. These are business days counted from the time the sample reaches the laboratory.
8. If the result is abnormal, a consultation with a clinical geneticist is included in the test price. During the phone consultation, the doctor explains the result and recommends further steps.

Prenatal testDNA 3 and RhD is non-invasive and can be performed by almost any pregnant woman. However, there are contraindications for the test.

The test cannot be performed in the following cases:

• Pregnancy with 3 or more fetuses.
• Pregnancy before the 10th week.
• Vanishing twin syndrome if fetal demise occurred after the 8th week of pregnancy or less than 8 weeks have passed between the demise and sample collection.
• Presence of tumor DNA in the mother's blood.
• Dichorionic twin pregnancy.
• Pregnant woman has an Rh-positive blood type.

In some situations, a specific waiting period before sample collection is recommended:

• It is recommended to wait 4 weeks after the last immunotherapy.
• It is recommended to wait 4 weeks after the last treatment with human plasma albumin.
• It is recommended to wait 12 months after a blood transfusion.
• Organ transplants and abnormal maternal karyotype (inversions, translocations, deletions, duplications, mosaicism) require prior consultation before testing. The test is not recommended for individuals who have undergone stem cell therapy.